The global adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2025-2034, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.
Base Year
Historical Year
Forecast Year
Value in USD Million
2025-2034
Adalimumab Biosimilar Market Outlook
*this image is indicative*
North America is expected to be one of the largest markets, owing to numerous large-scale testing laboratories worldwide. The rising incidence of rheumatoid arthritis and the growing geriatric population are among the major factors which are fuelling the market expansion in North America.
Due to extensive commercial advancements and growing biotechnology corporations in the province, Asia Pacific is anticipated to register sturdy growth over the projection period. The increasing focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel the global adalimumab biosimilar industry in the region.
Europe is expected to grow faster due to the rise in approvals of the new biosimilars, the ageing population, and increasing investments in the research and development of the new adalimumab biosimilars. For instance, in October 2018, Amgen Inc. launched AMGEVITA, a biosimilar of adalimumab.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Adalimumab is a monoclonal antibody used to treat autoimmune illnesses, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and others. It accomplishes this by blocking Tumour Necrosis Factor (TNF), a soluble inflammatory cytokine. This drug helps prevent further joint injury and preserve joint function by lowering joint swelling. "Adalimumab Biosimilar Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
By product, the market includes:
The several distribution channels of the market are:
Market Breakup by Region:
The most frequent illnesses that harm human health are skin disorders. Many skin disorders lead to lifelong disfigurement, stigma, and disability, and treating them effectively has become a significant concern for health organizations. In this context, a biosimilar of adalimumab has emerged as a feasible therapy option for persistent skin conditions like eczema. This aspect can significantly increase the size of the global adalimumab biosimilar industry throughout the forecast period. The multiple advantages, especially in treating psoriasis, adalimumab biosimilar is a preferred option for tackling skin disorders. The rising geriatric population and increasing public and private investment in pharmaceuticals will propel the market growth. Regulatory approvals for novel products motivate other companies to invest more in research and development and produce new inventions. Some global adalimumab biosimilar industry competitors are already working on new product development and portfolio expansion. For example, through a licencing deal with Cadila Healthcare, Glenmark Pharmaceuticals introduced ADALY, its adalimumab biosimilar medicine, in Mumbai in January 2018.
The report gives a detailed analysis of the following key players in the global adalimumab biosimilar industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is projected to grow at a CAGR of 17.60% between 2025 and 2034.
The major drivers of the market include the presence of numerous large-scale testing laboratories, rising incidence of rheumatoid arthritis, growing biotechnology corporations, increasing focus to develop generic and biosimilar products, rise in approvals of the new biosimilars, and growing investments in the research and development of the new adalimumab biosimilars.
The growing geriatric population and proliferation of skin disorders are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different products are exemptia, adalirel, and cipleumab, among others.
The several distribution channels in the global adalimumab biosimilar market are hospital pharmacies and retail pharmacies, among others.
The major players in the industry are Alfred E. Tiefenbacher (GmbH & Co. KG), Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Reliance Life Sciences Private Limited, among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share